COA of Formula: C13H11N3《Synthesis, characterization, X-ray crystal structures of heterocyclic Schiff base compounds and in vitro cholinesterase inhibition and anticancer activity》 was published in 2017. The authors were Arafath, Azharul Md.;Adam, Farook;Al-Suede, Fouad Saleih R.;Razali, Mohd. R.;Ahamed, Mohamed B. Khadeer;Abdul Majid, Amin Malik Shah;Hassan, Mohd. Zaheen;Osman, Hasnah;Abubakar, Saifullah, and the article was included in《Journal of Molecular Structure》. The author mentioned the following in the article:
Four heterocyclic embedded Schiff base derivatives, (benzimidazo[1,2-c]quinazolin-6-yl)methoxyphenol I and II [R = 3-OH-4-OMe, 2-OH-5-OMe; R1 = 5-methyl-2-pyridyl, 2-(1,3-benzothiazol-2-yl)phenyl] were synthesized and characterized by m.p., elemental anal., FTIR, 1H, 13C NMR and UV-visible spectral data. The structures of compounds I and II [R = 2-OH-5-OMe, R1 = 5-methyl-2-pyridyl; 3-OH-4-OMe, 2-(1,3-benzothiazol-2-yl)phenyl] were successfully established through single crystal X-ray diffraction anal. In-vitro cholinesterase inhibition assays showed that the cyclized derivative I displayed higher BuChE enzyme inhibitory activity with IC50 value of 1.45 ± 0.09 μM. The anti-proliferative efficacies of the compounds were also evaluated using human colorectal HCT 116 and breast MCF-7 adenocarcinoma cell lines. In addition, a human normal endothelial cell line (Ea.hy926) was also tested to assess the safety and selectivity of the compounds towards normal and cancer cells, resp. Among the compounds tested, compound II [R = 3-OH-4-OMe, 2-(1,3-benzothiazol-2-yl)phenyl] displayed potent cytotoxic effect (IC50 = 34 μM) against HCT 116 cells with highest selectivity index of 3.1 with respect to the normal endothelial cells. Whereas, compound II [R = 2-OH-5-OMe, R1 = 5-methyl-2-pyridyl] exhibited significant anti-proliferative effect (IC50 = 21.1 μM) against MCF-7 cells with highest selectivity index of 3.3 with respect to the normal endothelial cells. The docking result of these compounds against hAChE showed potent activities with different binding modes. These compounds could be a promising pharmacol. agent to treat cancer and Alzheimer’s disease. The experimental procedure involved many compounds, such as 2-(1H-Benzo[d]imidazol-2-yl)aniline (cas: 5805-39-0) .
2-(1H-Benzo[d]imidazol-2-yl)aniline(cas:5805-39-0 COA of Formula: C13H11N3) is a chemical reagent used in the synthesis of small molecule inhibitors targeting ubiquitin-like domains for treatments of diseases caused by the cellular accumulation of damaged proteins.
Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem